Company profile: Nimbus Therapeutics
1.1 - Company Overview
Company description
- Provider of computational drug discovery solutions using a platform that applies computational chemistry and structural biology to design selective small molecule therapeutics targeting disease-related proteins. Offerings include TYK2 and HPK1 inhibitors, AMPK activators, and ACC inhibitors for immune, metabolic, and liver disease indications such as psoriasis and NASH.
Products and services
- Acetyl-CoA Carboxylase (ACC) Inhibitors: Enzyme-targeted small molecule products that reduce fatty acid synthesis to address non-alcoholic steatohepatitis (NASH) and liver cancer by inhibiting ACC activity
- Computational Drug Discovery Engine: Research-grade platform using computational chemistry and structural biology to engineer selective small molecule therapeutics that target disease-involved proteins
- TYK2 Inhibitors: Selectivity-optimized small molecule assemblies that target tyrosine kinase 2 to treat immune-mediated diseases, specifically psoriasis, through TYK2 inhibition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nimbus Therapeutics
Aligos Therapeutics
HQ: United States
Website
- Description: Provider of small molecule and oligonucleotide platforms and a pipeline of drug candidates for MASH and viral diseases, including COVID-19 protease inhibitors (partly funded by NIH and NIAID), a capsid assembly modulator (ALG-000184) for chronic hepatitis B, STOPSTM to reduce HBV S-antigen, and next-generation antisense oligonucleotides (e.g., ALG-020572).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aligos Therapeutics company profile →
Callidus Biopharma
HQ: United States
Website
- Description: Provider of drug discovery focused on best-in-class enzyme replacement therapies for lysosomal storage disorders, using a novel technology platform that attaches a form of naturally occurring Insulin-like Growth Factor (IGF-2) to therapeutic enzymes to enhance targeting to relevant cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Callidus Biopharma company profile →
Clarus Therapeutics
HQ: United States
Website
- Description: Provider of androgen-based biopharmaceutical therapies, developing medicines for men and women, including JATENZO, an oral testosterone replacement therapy for men with conditions associated with a deficiency or absence of endogenous testosterone.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarus Therapeutics company profile →
CymaBay
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development and commercialization of proprietary new medicines for important human diseases, including Seladelpar—an investigational treatment for primary biliary cholangitis—and PBC-focused clinical trials such as IDEAL, AFFIRM, PBC with Hepatic Impairment, ASSURE, and RESPONSE.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CymaBay company profile →
Humedics
HQ: Germany
Website
- Description: Provider of rapid, precise liver function measurement via LiMAx, an easy-to-use bedside, non-invasive breath analysis test using 13C-labelled methacetin to assess liver function capacity. Offers LiMAx device development for surgical use with potential expansion into general healthcare, and supports investigator-initiated research. Applications include planning liver surgeries, patient selection, postoperative management, and assessing disease severity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Humedics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nimbus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nimbus Therapeutics
2.2 - Growth funds investing in similar companies to Nimbus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nimbus Therapeutics
4.2 - Public trading comparable groups for Nimbus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →